ENTA

Enanta Pharmaceuticals, Inc

11.22

USD

-0.25

-2.18%

Nov 10, 15:59 UTC -5

Closed

After-Market

11.22

0.00

+0.04%

Enanta Pharmaceuticals, Inc (ENTA) Earnings

ENTA Earnings Reports

Positive Surprise Ratio

ENTA beat 27 of 42 last estimates.

64%

Next Report

Next Week

Date of Next Report

Nov 16, 2026

Estimate for Q4 26 (Revenue/ EPS)

$14.48M

-$0.79

Implied change from Q3 26 (Revenue/ EPS)

+0.87%

+17.91%

Implied change from Q4 25 (Revenue/ EPS)

-4.24%

-9.20%

Enanta Pharmaceuticals, Inc earnings per share and revenue

On Aug 10, 2026, ENTA reported earnings of -0.67 USD per share (EPS) for Q3 26, missing the estimate of -0.52 USD, resulting in a -28.80% surprise. Revenue reached 14.36 million, compared to an expected 17.13 million, with a -16.19% difference. The market reacted with a -2.10% price change (close before vs. close after earnings).

Looking ahead to Q4 26, 6 analysts forecast an EPS of -0.79 USD, with revenue projected to reach 14.48 million USD, implying an increase of 17.91% EPS, and increase of 0.87% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Enanta Pharmaceuticals, Inc's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Enanta Pharmaceuticals, Inc reported EPS of -$0.67, missing estimates by -28.8%, and revenue of $14.36M, -16.19% below expectations.

How did the market react to Enanta Pharmaceuticals, Inc's Q3 2026 earnings?

The stock price moved down -2.1%, changed from $13.81 before the earnings release to $13.52 the day after.

When is Enanta Pharmaceuticals, Inc expected to report next?

The next earning report is scheduled for Nov 16, 2026.

What are the forecasts for Enanta Pharmaceuticals, Inc's next earnings report?

Based on 6 analysts, Enanta Pharmaceuticals, Inc is expected to report EPS of -$0.79 and revenue of $14.48M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.